JP2015504067A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504067A5 JP2015504067A5 JP2014550773A JP2014550773A JP2015504067A5 JP 2015504067 A5 JP2015504067 A5 JP 2015504067A5 JP 2014550773 A JP2014550773 A JP 2014550773A JP 2014550773 A JP2014550773 A JP 2014550773A JP 2015504067 A5 JP2015504067 A5 JP 2015504067A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- substituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- 239000011780 sodium chloride Substances 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 102100010563 SCN9A Human genes 0.000 claims 3
- 101700051996 SCN9A Proteins 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000004429 atoms Chemical group 0.000 claims 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000004296 Neuralgia Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261582916P | 2012-01-04 | 2012-01-04 | |
US61/582,916 | 2012-01-04 | ||
PCT/IB2012/057625 WO2013102826A1 (en) | 2012-01-04 | 2012-12-21 | N-aminosulfonyl benzamides |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015504067A JP2015504067A (ja) | 2015-02-05 |
JP2015504067A5 true JP2015504067A5 (US06780888-20040824-C00057.png) | 2016-01-28 |
JP6067031B2 JP6067031B2 (ja) | 2017-01-25 |
Family
ID=47722322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014550773A Expired - Fee Related JP6067031B2 (ja) | 2012-01-04 | 2012-12-21 | N−アミノスルホニルベンズアミド |
Country Status (5)
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
BR112014010271A2 (pt) | 2011-10-31 | 2017-04-18 | Xenon Pharmaceuticals Inc | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
CA2878478A1 (en) * | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
RU2015143834A (ru) | 2013-03-15 | 2017-04-24 | Дженентек, Инк. | Замещенные бензоксазолы и способы их применения |
CA2931732A1 (en) * | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CN105439946B (zh) * | 2014-08-13 | 2018-02-02 | 益方生物科技(上海)有限公司 | 羧酸化合物及其制备方法和用途 |
KR20180008761A (ko) | 2015-05-22 | 2018-01-24 | 제넨테크, 인크. | 치환된 벤즈아미드 및 이의 이용 방법 |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
WO2017091592A1 (en) | 2015-11-25 | 2017-06-01 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
AU2016370554B2 (en) | 2015-12-18 | 2018-11-29 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
MX2019004232A (es) | 2016-10-17 | 2019-08-01 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos. |
RS60209B1 (sr) | 2017-03-20 | 2020-06-30 | Forma Therapeutics Inc | Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr) |
CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
TW201920107A (zh) | 2017-08-31 | 2019-06-01 | 日商拉夸里亞創藥股份有限公司 | 作為ttx-s阻斷劑之雙芳氧基衍生物 |
WO2019165290A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
HUE057970T2 (hu) | 2018-03-08 | 2022-06-28 | Incyte Corp | Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok |
EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
WO2021132577A1 (ja) * | 2019-12-27 | 2021-07-01 | 日本たばこ産業株式会社 | アシルスルファミド化合物及びその医薬用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
GB9828442D0 (en) * | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
EP1673357A2 (en) | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
PT2076508E (pt) | 2006-10-18 | 2011-03-07 | Pfizer Prod Inc | Compostos de ureia de éter biarílico |
US8357711B2 (en) | 2007-03-23 | 2013-01-22 | Pfizer Limited | Heterocyclic sulfonamides as inhibitors of ion channels |
KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
WO2009054468A1 (ja) * | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | アゾールカルボキサミド化合物又はその塩 |
BRPI1006128A2 (pt) * | 2009-01-12 | 2016-11-01 | Cagen Inc | derivados de sulfonamida |
EP2593432B1 (en) * | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
US8772343B2 (en) * | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
ES2532357T3 (es) * | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
CA2804716A1 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
EP2791108B1 (en) * | 2011-12-15 | 2016-07-27 | Pfizer Limited | Sulfonamide derivatives |
-
2012
- 2012-12-21 WO PCT/IB2012/057625 patent/WO2013102826A1/en active Application Filing
- 2012-12-21 CA CA2860553A patent/CA2860553C/en not_active Expired - Fee Related
- 2012-12-21 US US14/358,603 patent/US20150291514A1/en not_active Abandoned
- 2012-12-21 JP JP2014550773A patent/JP6067031B2/ja not_active Expired - Fee Related
- 2012-12-21 EP EP12824810.1A patent/EP2800740A1/en not_active Withdrawn